1333468-54-4

Basic information

• Product Name: 2-Chloro-4-(4-fluoro-2-methoxyphenyl)pyridine
• Synonyms: 2-Chloro-4-(4-fluoro-2-methoxyphenyl)pyridine
• CAS NO: 1333468-54-4
• Molecular Formula: C₁₂H₉ClFNO
• Molecular Weight: 237.6573632
• Mol File: 1333468-54-4.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Chloro-4-(4-fluoro-2-methoxyphenyl)pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-4-(4-fluoro-2-methoxyphenyl)pyridine(1333468-54-4)
• EPA Substance Registry System: 2-Chloro-4-(4-fluoro-2-methoxyphenyl)pyridine(1333468-54-4)

Safety Data

• Hazardous Substances Data: 1333468-54-4(Hazardous Substances Data)

Upstream product

• 73583-37-6 2-chloro-4-bromopyridine 
• 179899-07-1 4-fluoro-2-methoxyphenylboronic acid 

Downstream Products

• 1333468-16-8 N-(4-(4-fluoro-2-methoxyphenyl)pyridin-2-yl)cyclohexanecarboxamide hydrochloride 
• 1395493-47-6 [3-((4-(4-fluoro-2-methoxyphenyl)pyridin-2-yl)amino)phenyl]methanesulfonamide 
• 1333467-73-4 N-(4-(4-Fluoro-2-methoxyphenyl)pyridin-2-yl)cyclohexanecarboxamide 

Relevant articles and documents

Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer

Selective inhibition of exclusively transcription-regulating positive transcription elongation factor b/CDK9 is a promising new approach in cancer therapy. Starting from atuveciclib, the first selective CDK9 inhibitor to enter clinical development, lead optimization efforts aimed at identifying intravenously (iv) applicable CDK9 inhibitors with an improved therapeutic index led to the discovery of the highly potent and selective clinical candidate VIP152. The evaluation of various scaffold hops was instrumental in the identification of VIP152, which is characterized by the underexplored benzyl sulfoximine group. VIP152 exhibited the best preclinical overall profile in vitro and in vivo, including high efficacy and good tolerability in xenograft models in mice and rats upon once weekly iv administration. VIP152 has entered clinical trials for the treatment of cancer with promising longterm, durable monotherapy activity in double-hit diffuse large B-cell lymphoma patients.

Inhibitors of protein kinases

Compounds of general Formula (I): wherein R1, R2, R3, Ra, A, B and x are as defined herein are inhibitors of protein kinases in particular members of the cyclin-dependent kinase family and/or the glycogen synthase kinase 3 family and are useful in preventing and/or treating any type of pain, inflammatory disorders, cancer, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases, metabolic disorders, renal diseases, neurologic and neuropsychiatric diseases and neurodegenerative diseases.